T1	tradename 108 115	Marqibo
T2	activeingredient 116 134	vinCRIStinesulfate
T3	nanoparticle 134 142	LIPOSOME
T4	tradename 205 212	Marqibo
T5	activeingredient 213 231	vinCRIStinesulfate
T6	nanoparticle 231 239	LIPOSOME
T7	tradename 251 258	Marqibo
T8	activeingredient 259 277	vinCRIStinesulfate
T9	nanoparticle 277 285	LIPOSOME
T10	routeofadministration 298 309	intravenous
T11	fdaapprovaldate 337 341	2012
T12	routeofadministration 415 426	Intravenous
T13	tradename 510 517	Marqibo
T14	activeingredient 518 536	vinCRIStinesulfate
T15	nanoparticle 536 544	LIPOSOME
T16	activeingredient 592 610	vinCRIStinesulfate
T17	tradename 714 721	Marqibo
T18	chemoclass 724 737	vincaalkaloid
T19	indication 780 845	Philadelphiachromosomenegative(Ph)acutelymphoblasticleukemia(ALL)
T20	routeofadministration 1077 1088	Intravenous
T21	tradename 1139 1146	Marqibo
T22	dose 1155 1164	2.25mg/m2
T23	routeofadministration 1164 1177	intravenously
T24	frequency 1186 1200	onceevery7days
T25	tradename 1287 1294	Marqibo
T26	tradename 1335 1342	Marqibo
T27	activeingredient 1343 1361	vinCRIStinesulfate
T28	nanoparticle 1361 1369	LIPOSOME
T29	activeingredient 1406 1424	vincristinesulfate
T30	tradename 1453 1460	Marqibo
T31	tradename 1554 1561	Marqibo
T32	activeingredient 1611 1629	vincristinesulfate
T33	tradename 1656 1663	Marqibo
T34	activeingredient 1664 1682	vinCRIStinesulfate
T35	nanoparticle 1682 1690	LIPOSOME
T36	tradename 1707 1714	Marqibo
T37	tradename 2060 2067	Marqibo
T38	tradename 2169 2177	Marqibo.
T39	tradename 2231 2238	Marqibo
T40	adversereaction 2809 2822	constipation,
T41	adversereaction 2822 2829	nausea,
T42	adversereaction 2829 2837	pyrexia,
T43	adversereaction 2837 2845	fatigue,
T44	adversereaction 2845 2866	peripheralneuropathy,
T45	adversereaction 2866 2885	febrileneutropenia,
T46	adversereaction 2885 2894	diarrhea,
T47	adversereaction 2894 2901	anemia,
T48	adversereaction 2901 2919	decreasedappetite,
T49	adversereaction 2922 2930	insomnia
T50	company 2978 2995	TalonTherapeutics
T51	tradename 3066 3073	Marqibo
T52	activeingredient 3133 3151	vincristinesulfate
T53	tradename 3220 3227	Marqibo
T54	routeofadministration 3382 3393	INTRAVENOUS
T55	indication 3427 3435	AdultALL
T56	routeofadministration 3657 3668	Intravenous
T57	adversereaction 3680 3705	ExtravasationTissueInjury
T58	adversereaction 3710 3728	NeurologicToxicity
T59	adversereaction 3733 3749	Myelosuppression
T60	adversereaction 3755 3773	TumorLysisSyndrome
T61	adversereaction 3778 3809	ConstipationandBowelObstruction
T62	adversereaction 3814 3821	Fatigue
T63	adversereaction 3826 3841	HepaticToxicity
T64	adversereaction 3846 3865	EmbryofetalToxicity
T65	indication 4570 4596	AcuteLymphoblasticLeukemia
T66	routeofadministration 4691 4702	Intravenous
T67	routeofadministration 4795 4806	intrathecal
T68	tradename 4824 4831	Marqibo
T69	activeingredient 4832 4850	vinCRIStinesulfate
T70	nanoparticle 4850 4858	LIPOSOME
T71	activeingredient 4906 4924	vinCRIStinesulfate
T72	indication 5034 5042	AdultALL
T73	tradename 5066 5073	Marqibo
T74	indication 5118 5183	Philadelphiachromosomenegative(Ph)acutelymphoblasticleukemia(ALL)
T75	routeofadministration 5414 5425	Intravenous
T76	tradename 5461 5468	Marqibo
T77	activeingredient 5469 5487	vinCRIStinesulfate
T78	nanoparticle 5487 5495	LIPOSOME
T79	activeingredient 5542 5560	vincristinesulfate
T80	tradename 5687 5694	Marqibo
T81	dose 5696 5705	2.25mg/m2
T82	routeofadministration 5705 5718	intravenously
T83	frequency 5727 5742	onceevery7days.
T84	tradename 5743 5750	Marqibo
T85	nanoparticle 5752 5772	liposomeencapsulated
T86	activeingredient 5772 5784	vincristine.
T87	tradename 5828 5835	Marqibo
T88	tradename 6010 6017	Marqibo
T89	tradename 6304 6318	Marqiborelated
T90	tradename 6466 6474	Marqibo.
T91	tradename 6623 6631	Marqibo.
T92	tradename 6727 6734	Marqibo
T93	dose 6740 6747	2mg/m2.
T94	tradename 6798 6805	Marqibo
T95	dose 6901 6908	2mg/m2:
T96	tradename 6924 6932	Marqibo.
T97	tradename 6983 6990	Marqibo
T98	dose 6996 7007	1.825mg/m2.
T99	tradename 7059 7066	Marqibo
T100	dose 7163 7174	1.825mg/m2:
T101	tradename 7190 7198	Marqibo.
T102	tradename 7238 7245	Marqibo
T103	dose 7251 7260	1.5mg/m2.
T104	tradename 7658 7665	Marqibo
T105	tradename 7669 7676	Marqibo
T106	tradename 8032 8039	Marqibo
T107	tradename 8106 8113	Marqibo
T108	activeingredient 8115 8134	vinCRIStine sulfate
T109	nanoparticle 8135 8143	LIPOSOME
T110	tradename 8393 8401	Marqibo.
T111	tradename 8401 8408	Marqibo
T112	tradename 8505 8512	Marqibo
T113	tradename 8675 8683	Marqibo.
T114	tradename 8704 8711	Marqibo
T115	nanoparticle 8781 8789	Liposome
T116	activeingredient 8802 8820	VinCRIStineSulfate
T117	tradename 9587 9594	Marqibo
T118	nanoparticle 10049 10057	Liposome
T119	activeingredient 10069 10087	VinCRIStineSulfate
T120	nanoparticle 10140 10148	Liposome
T121	nanoparticle 10198 10206	Liposome
T122	inactiveingredient 10222 10237	SodiumPhosphate
T123	activeingredient 10268 10286	VinCRIStineSulfate
T124	activeingredient 10310 10328	VinCRIStineSulfate
T125	inactiveingredient 10344 10359	SodiumPhosphate
T126	inactiveingredient 10416 10431	SodiumPhosphate
T127	inactiveingredient 10507 10522	SodiumPhosphate
T128	inactiveingredient 10626 10641	SodiumPhosphate
T129	activeingredient 10664 10682	VinCRIStineSulfate
T130	nanoparticle 10717 10725	Liposome
T131	inactiveingredient 10738 10753	SodiumPhosphate
T132	inactiveingredient 10958 10973	SodiumPhosphate
T133	tradename 11058 11065	Marqibo
T134	tradename 11313 11320	Marqibo
T135	inactiveingredient 11419 11434	SodiumPhosphate
T136	tradename 11473 11480	Marqibo
T137	activeingredient 11482 11500	vinCRIStinesulfate
T138	nanoparticle 11500 11508	LIPOSOME
T139	tradename 11687 11694	Marqibo
T140	activeingredient 11695 11713	vinCRIStinesulfate
T141	nanoparticle 11713 11721	LIPOSOME
T142	activeingredient 11758 11777	vincristinesulfate.
T143	tradename 11899 11906	Marqibo
T144	tradename 12011 12018	Marqibo
T145	tradename 12126 12133	Marqibo
T146	tradename 12239 12246	Marqibo
T147	tradename 12445 12452	Marqibo
T148	activeingredient 12603 12621	vincristinesulfate
T149	nanoparticle 12628 12638	liposomes.
T150	tradename 13000 13007	Marqibo
T151	tradename 13039 13046	Marqibo
T152	tradename 13126 13133	Marqibo
T153	activeingredient 13134 13152	vinCRIStinesulfate
T154	nanoparticle 13152 13160	LIPOSOME
T155	activeingredient 13197 13216	vincristinesulfate.
T156	tradename 13236 13243	Marqibo
T157	tradename 13333 13340	Marqibo
T158	activeingredient 13389 13407	vincristinesulfate
T159	tradename 13434 13441	Marqibo
T160	activeingredient 13442 13460	vinCRIStinesulfate
T161	nanoparticle 13460 13468	LIPOSOME
T162	tradename 13480 13487	Marqibo
T163	routeofadministration 13565 13576	Intravenous
T164	tradename 14298 14305	Marqibo
T165	indication 14462 14470	adultALL
T166	tradename 14594 14601	Marqibo
T167	adversereaction 14643 14659	Myelosuppression
T168	tradename 14702 14710	Marqibo.
T169	adversereaction 14721 14733	neutropenia,
T170	adversereaction 14733 14750	thrombocytopenia,
T171	adversereaction 14752 14758	anemia
T172	tradename 14775 14782	Marqibo
T173	adversereaction 14845 14886	TumorLysisSyndromeTumorlysissyndrome(TLS)
T174	indication 14908 14911	ALL
T175	tradename 14920 14928	Marqibo.
T176	adversereaction 14965 15002	ConstipationandBowelObstructionIleus,
T177	adversereaction 15002 15019	bowelobstruction,
T178	adversereaction 15022 15046	colonicpseudoobstruction
T179	tradename 15059 15066	Marqibo
T180	adversereaction 15074 15086	constipation
T181	adversereaction 15168 15181	constipation,
T182	adversereaction 15181 15198	bowelobstruction,
T183	adversereaction 15204 15219	paralyticileus,
T184	adversereaction 15421 15428	Fatigue
T185	tradename 15428 15435	Marqibo
T186	adversereaction 15449 15457	fatigue.
T187	tradename 15457 15464	Marqibo
T188	adversereaction 15521 15554	HepaticToxicityFatallivertoxicity
T189	adversereaction 15557 15598	elevatedlevelsofaspartateaminotransferase
T190	adversereaction 15611 15652	Elevatedlevelsofaspartateaminotransferase
T191	tradename 15747 15754	Marqibo
T192	adversereaction 15757 15773	hepatictoxicity.
T193	adversereaction 15778 15797	EmbryofetalToxicity
T194	tradename 15797 15804	Marqibo
T195	activeingredient 15854 15872	Vincristinesulfate
T196	nanoparticle 15872 15880	liposome
T197	tradename 16013 16021	Marqibo.
T198	tradename 16065 16072	Marqibo
T199	tradename 16149 16156	Marqibo
T200	routeofadministration 16457 16468	intravenous
T201	adversereaction 16515 16540	Extravasationtissueinjury
T202	adversereaction 16579 16599	PeripheralNeuropathy
T203	adversereaction 16638 16654	Myelosuppression
T204	adversereaction 16693 16711	Tumorlysissyndrome
T205	adversereaction 16750 16781	Constipationandbowelobstruction
T206	adversereaction 16820 16827	Fatigue
T207	adversereaction 16866 16881	Hepatictoxicity
T208	indication 17285 17323	Ph- Adult Acute Lymphoblastic Leukemia
T209	tradename 17324 17332	Marqibo,
T210	dose 17341 17350	2.25mg/m2
T211	frequency 17350 17357	weekly,
T212	adversereaction 17502 17514	constipation
T213	adversereaction 17520 17526	nausea
T214	adversereaction 17532 17539	pyrexia
T215	adversereaction 17545 17552	fatigue
T216	adversereaction 17558 17578	peripheralneuropathy
T217	adversereaction 17584 17602	febrileneutropenia
T218	adversereaction 17608 17616	diarrhea
T219	adversereaction 17622 17628	anemia
T220	adversereaction 17634 17651	decreasedappetite
T221	adversereaction 17660 17668	insomnia
T222	adversereaction 18080 18098	FebrileNeutropenia
T223	adversereaction 18107 18118	Neutropenia
T224	adversereaction 18127 18133	Anemia
T225	adversereaction 18142 18158	Thrombocytopenia
T226	adversereaction 18190 18199	Pneumonia
T227	adversereaction 18206 18217	SepticShock
T228	adversereaction 18224 18248	StaphylococcalBacteremia
T229	adversereaction 18279 18314	PeripheralSensoryandMotorNeuropathy
T230	adversereaction 18324 18336	Constipation
T231	adversereaction 18345 18375	Ileus,ColonicPseudoObstruction
T232	adversereaction 18383 18391	Asthenia
T233	adversereaction 18400 18416	MuscularWeakness
T234	adversereaction 18482 18501	RespiratoryDistress
T235	adversereaction 18509 18527	RespiratoryFailure
T236	adversereaction 18598 18605	Pyrexia
T237	adversereaction 18614 18621	Fatigue
T238	adversereaction 18630 18634	Pain
T239	adversereaction 18680 18693	AbdominalPain
T240	adversereaction 18727 18761	AspartateAminotransferaseIncreased
T241	adversereaction 18797 18808	Hypotension
T242	adversereaction 18849 18868	MentalStatusChanges
T243	adversereaction 18904 18917	CardiacArrest
T244	adversereaction 19264 19282	febrileneutropenia
T245	adversereaction 19290 19297	pyrexia
T246	adversereaction 19305 19316	hypotension
T247	adversereaction 19323 19342	respiratorydistress
T248	adversereaction 19352 19365	cardiacarrest
T249	adversereaction 19602 19622	peripheralneuropathy
T250	adversereaction 19651 19669	tumorlysissyndrome
T251	adversereaction 19802 19826	decreasedvibratorysense,
T252	adversereaction 19826 19838	facialpalsy,
T253	adversereaction 19838 19851	hyporeflexia,
T254	adversereaction 19851 19864	constipation,
T255	adversereaction 19864 19873	asthenia,
T256	adversereaction 19873 19881	fatigue,
T257	adversereaction 19884 19904	musculoskeletalpain,
T258	tradename 20265 20273	Marqibo.
T259	tradename 20273 20280	Marqibo
T260	activeingredient 20340 20359	vincristinesulfate.
T261	routeofadministration 20372 20376	oral
T262	routeofadministration 20378 20389	intravenous
T263	co-administereddrug 20405 20414	phenytoin
T264	co-administereddrug 20417 20443	antineoplasticchemotherapy
T265	activeingredient 20479 20497	vincristinesulfate
T266	activeingredient 20594 20613	Vincristinesulfate,
T267	tradename 20629 20637	Marqibo,
T268	activeingredient 21105 21124	Vincristinesulfate,
T269	tradename 21140 21148	Marqibo,
T270	tradename 21338 21346	Marqibo.
T271	tradename 21569 21576	Marqibo
T272	activeingredient 21824 21842	vincristinesulfate
T273	nanoparticle 21842 21850	liposome
T274	routeofadministration 21859 21872	intravenously
T275	activeingredient 21904 21922	vincristinesulfate
T276	dose 21929 21945	0.022to0.09mg/kg
T277	frequency 21945 21950	/day.
T278	dose 22171 22181	0.044mg/kg
T279	frequency 22181 22185	/day
T280	tradename 22613 22620	Marqibo
T281	tradename 23064 23071	Marqibo
T282	activeingredient 23125 23143	vincristinesulfate
T283	tradename 23234 23241	Marqibo
T284	tradename 23283 23290	Marqibo
T285	tradename 23480 23487	Marqibo
T286	tradename 23626 23633	Marqibo
T287	activeingredient 23634 23652	vinCRIStinesulfate
T288	nanoparticle 23652 23660	LIPOSOME
T289	dose 23694 23703	2.4mg/m2,
T290	adversereaction 23728 23743	motorneuropathy
T291	adversereaction 23752 23767	grandmalseizure
T292	adversereaction 23779 23812	elevatedaspartateaminotransferase
T293	adversereaction 23815 23833	hyperbilirubinemia
T294	tradename 23919 23926	Marqibo
T295	activeingredient 23927 23945	vinCRIStinesulfate
T296	nanoparticle 23945 23953	LIPOSOME
T297	activeingredient 23965 23976	vincristine
T298	corecomposition 23990 24015	sphingomyelin/cholesterol
T299	nanoparticle 24015 24024	liposomes
T300	routeofadministration 24027 24038	intravenous
T301	tradename 24075 24082	Marqibo
T302	activeingredient 24084 24103	vincristinesulfate.
T303	activeingredient 24103 24121	Vincristinesulfate
T304	chemoclass 24124 24137	vincaalkaloid
T305	molecularweight 24309 24315	923.04
T306	molecularweight 24326 24332	824.98
T307	activeingredient 24408 24426	vincristinesulfate
T308	activeingredient 24490 24501	Vincristine
T309	corecomposition 24518 24543	Sphingomyelin/Cholesterol
T310	nanoparticle 24543 24552	liposome.
T311	nanoparticle 24575 24583	liposome
T312	corecomposition 24586 24599	sphingomyelin
T313	corecomposition 24602 24613	cholesterol
T314	tradename 24684 24691	Marqibo
T315	activeingredient 24702 24721	vincristinesulfate,
T316	inactiveingredient 24726 24735	mannitol,
T317	corecomposition 24741 24755	sphingomyelin,
T318	corecomposition 24761 24773	cholesterol,
T319	inactiveingredient 24777 24791	sodiumcitrate,
T320	inactiveingredient 24795 24806	citricacid,
T321	inactiveingredient 24811 24827	sodiumphosphate,
T322	inactiveingredient 24835 24850	sodiumchloride.
T323	tradename 24907 24914	Marqibo
T324	activeingredient 24915 24933	vinCRIStinesulfate
T325	nanoparticle 24933 24941	LIPOSOME
T326	corecomposition 25061 25086	sphingomyelin/cholesterol
T327	nanoparticle 25086 25096	liposomes,
T328	nanoparticle 25113 25121	liposome
T329	particlediameter 25135 25141	100nm.
T330	nanoparticle 25183 25193	liposomes.
T331	tradename 25197 25204	Marqibo
T332	tradename 25240 25247	Marqibo
T333	activeingredient 25248 25266	vinCRIStinesulfate
T334	nanoparticle 25266 25274	LIPOSOME
T335	activeingredient 25296 25314	VinCRIStineSulfate
T336	activeingredient 25341 25359	VinCRIStineSulfate
T337	activeingredient 25389 25407	vincristinesulfate
T338	activeingredient 25436 25447	vincristine
T339	inactiveingredient 25468 25477	mannitol.
T340	corecomposition 25481 25506	Sphingomyelin/Cholesterol
T341	nanoparticle 25506 25514	Liposome
T342	corecomposition 25538 25563	Sphingomyelin/Cholesterol
T343	nanoparticle 25563 25571	Liposome
T344	corecomposition 25603 25617	sphingomyelin,
T345	corecomposition 25626 25638	cholesterol,
T346	inactiveingredient 25647 25658	citricacid,
T347	inactiveingredient 25667 25681	sodiumcitrate,
T348	inactiveingredient 25711 25726	SodiumPhosphate
T349	inactiveingredient 25752 25767	SodiumPhosphate
T350	inactiveingredient 25800 25822	dibasicsodiumphosphate
T351	inactiveingredient 25835 25850	sodiumchloride.
T352	tradename 25896 25903	Marqibo
T353	corecomposition 25906 25931	sphingomyelin/cholesterol
T354	nanoparticle 25931 25951	liposomeencapsulated
T355	activeingredient 25964 25983	vincristinesulfate.
T356	activeingredient 25995 26013	vincristinesulfate
T357	activeingredient 26134 26152	vincristinesulfate
T358	tradename 26311 26318	Marqibo
T359	indication 26362 26365	ALL
T360	tradename 26377 26384	Marqibo
T361	dose 26390 26399	2.25mg/m2
T362	routeofadministration 26419 26430	intravenous
T363	activeingredient 26491 26509	vincristinesulfate
T364	activeingredient 26530 26548	vincristinesulfate
T365	nanoparticle 26577 26597	liposomeencapsulated
T366	activeingredient 26681 26699	vincristinesulfate
T367	activeingredient 26732 26751	vincristinesulfate,
T368	indication 26832 26858	AcuteLymphoblasticLeukemia
T369	dose 26869 26878	2.25mg/m2
T370	tradename 26878 26886	Marqiboa
T371	auc 26926 26931	14566
T372	auc 26943 26968	703626074(h&#x2022;ng/mL)
T373	clearance 26974 26977	345
T374	clearance 26986 26998	148783(mL/h)
T375	cmax 27006 27010	1220
T376	cmax 27019 27033	9191720(ng/mL)
T377	tradename 27096 27103	Marqibo
T378	clearance 27110 27118	345mL/h,
T379	dose 27127 27137	2.25mg/m2.
T380	activeingredient 27189 27207	vincristinesulfate
T381	clearance 27209 27221	189mL/min/m2
T382	clearance 27222 27233	11,340mL/h)
T383	tradename 27252 27259	Marqibo
T384	tradename 27289 27296	Marqibo
T385	activeingredient 27318 27337	vincristinesulfate.
T386	routeofadministration 27397 27408	intravenous
T387	tradename 27424 27432	Marqibo,
T388	activeingredient 27478 27496	vincristinesulfate
T389	tradename 27540 27547	Marqibo
T390	activeingredient 27649 27668	vincristinesulfate.
T391	activeingredient 27689 27707	vincristinesulfate
T392	activeingredient 27730 27748	vincristinesulfate
T393	tradename 27946 27953	Marqibo
T394	activeingredient 27967 27986	vincristinesulfate.
T395	activeingredient 28081 28100	vincristinesulfate,
T396	tradename 28100 28107	Marqibo
T397	tradename 28168 28176	Marqibo.
T398	activeingredient 28188 28199	vincristine
T399	tradename 28305 28312	Marqibo
T400	activeingredient 28376 28395	vincristinesulfate.
T401	activeingredient 28411 28422	vincristine
T402	nanoparticle 28422 28430	liposome
T403	activeingredient 28633 28652	vincristinesulfate.
T404	activeingredient 28862 28880	vincristinesulfate
T405	nanoparticle 28880 28888	liposome
T406	activeingredient 28911 28929	vincristinesulfate
T407	routeofadministration 28953 28966	intravenously
T408	frequency 28966 28987	onceperweekfor6weeks.
T409	activeingredient 29052 29070	vincristinesulfate
T410	nanoparticle 29070 29078	liposome
T411	activeingredient 29107 29125	vincristinesulfate
T412	activeingredient 29132 29150	vincristinesulfate
T413	dose 29157 29163	2mg/m2
T414	frequency 29163 29168	/week
T415	activeingredient 29384 29402	vincristinesulfate
T416	nanoparticle 29402 29410	liposome
T417	activeingredient 29543 29562	vincristinesulfate.
T418	dose 29619 29625	2mg/m2
T419	routeofadministration 29627 29638	intravenous
T420	nanoparticle 29638 29647	liposomal
T421	activeingredient 29661 29679	vincristinesulfate
T422	activeingredient 29706 29724	vincristinesulfate
T423	activeingredient 29813 29831	vincristinesulfate
T424	nanoparticle 29831 29839	liposome
T425	indication 29873 29899	AcuteLymphoblasticLeukemia
T426	tradename 29899 29906	Marqibo
T427	indication 30022 30055	PhiladelphiachromosomenegativeALL
T428	routeofadministration 30427 30438	intravenous
T429	tradename 30438 30445	Marqibo
T430	dose 30458 30467	2.25mg/m2
T431	frequency 30480 30491	every7days.
T432	tradename 30608 30616	Marqibo.
T433	activeingredient 30655 30673	vincristinesulfate
T434	indication 31036 31039	ALL
T435	indication 31059 31063	ALL.
T436	tradename 32458 32465	Marqibo
T437	activeingredient 32510 32528	VinCRIStineSulfate
T438	nanoparticle 32619 32627	Liposome
T439	inactiveingredient 32682 32697	SodiumPhosphate
T440	inactiveingredient 32778 32793	SodiumPhosphate
T441	tradename 32827 32834	Marqibo
T442	activeingredient 32835 32853	vinCRIStinesulfate
T443	nanoparticle 32854 32862	LIPOSOME
T444	tradename 32976 32983	Marqibo
T445	tradename 33135 33143	Marqibo:
T446	adversereaction 33144 33170	ExtravasationTissueInjury:
T447	tradename 33353 33360	Marqibo
T448	adversereaction 33368 33375	fatigue
T449	adversereaction 33388 33409	peripheralneuropathy.
T450	adversereaction 33527 33557	Gastrointestinal/Constipation:
T451	tradename 33574 33581	Marqibo
T452	adversereaction 33594 33607	constipation.
T453	adversereaction 33631 33643	constipation
T454	adversereaction 33812 33824	constipation
T455	adversereaction 33828 33853	bowelmovementinfrequency,
T456	adversereaction 33853 33867	abdominalpain,
T457	adversereaction 33867 33876	bloating,
T458	adversereaction 33876 33885	diarrhea,
T459	adversereaction 33885 33892	nausea,
T460	adversereaction 33894 33902	vomiting
T461	tradename 34043 34050	Marqibo
T462	tradename 34189 34196	Marqibo
T463	activeingredient 34959 34977	VinCRIStineSulfate
T464	company 34987 35006	USPHospiraAustralia
T465	nanoparticle 35068 35076	Liposome
T466	company 35085 35103	CangeneCorporation
T467	inactiveingredient 35133 35148	SodiumPhosphate
T468	company 35157 35179	JubilantHollisterStier
T469	tradename 35195 35202	Marqibo
T470	activeingredient 35224 35242	vinCRIStinesulfate
T471	nanoparticle 35242 35250	LIPOSOME
T472	company 35259 35280	AndersonPackaging,Inc
T473	company 35311 35333	TalonTherapeutics,Inc.
T474	tradename 35477 35484	Marqibo
T475	activeingredient 35497 35515	vinCRIStinesulfate
T476	nanoparticle 35515 35523	LIPOSOME
T477	tradename 35584 35591	Marqibo
T478	tradename 35604 35611	Marqibo
T479	tradename 35749 35764	Marqibo Marqibo
T480	indication 35808 35873	Philadelphiachromosomenegative(Ph)acutelymphoblasticleukemia(ALL)
T481	tradename 36043 36050	Marqibo
T482	tradename 36109 36117	Marqibo:
T483	tradename 36236 36243	Marqibo
T484	activeingredient 36317 36335	vincristinesulfate
T485	tradename 36358 36366	Marqibo.
T486	tradename 36411 36419	Marqibo.
T487	tradename 36464 36471	Marqibo
T488	routeofadministration 36510 36525	intravenous(IV)
T489	tradename 36573 36581	Marqibo?
T490	tradename 36597 36605	Marqibo,
T491	activeingredient 36655 36673	vincristinesulfate
T492	adversereaction 36871 36884	constipation,
T493	tradename 36986 36993	Marqibo
T494	tradename 37053 37061	Marqibo.
T495	tradename 37115 37123	Marqibo.
T496	tradename 37177 37185	Marqibo.
T497	tradename 37298 37305	Marqibo
T498	tradename 37370 37377	Marqibo
T499	tradename 37531 37538	Marqibo
T500	tradename 37601 37608	Marqibo
T501	tradename 37722 37730	Marqibo?
T502	tradename 37748 37755	Marqibo
T503	routeofadministration 37759 37774	intravenous(IV)
T504	tradename 37802 37809	Marqibo
T505	frequency 37823 37834	every7days.
T506	tradename 37873 37880	Marqibo
T507	tradename 37913 37920	Marqibo
T508	tradename 38012 38020	Marqibo.
T509	tradename 38051 38059	Marqibo?
T510	tradename 38063 38070	Marqibo
T511	adversereaction 38088 38096	fatigue)
T512	adversereaction 38113 38124	neuropathy)
T513	tradename 38233 38241	Marqibo?
T514	tradename 38281 38289	Marqibo?
T515	tradename 38290 38297	Marqibo
T516	adversereaction 38338 38351	Tissueinjury.
T517	tradename 38353 38360	Marqibo
T518	adversereaction 38575 38586	neuropathy)
T519	tradename 38614 38621	Marqibo
T520	tradename 38708 38715	Marqibo
T521	adversereaction 39450 39469	Lowbloodcellcounts.
T522	tradename 39470 39477	Marqibo
T523	adversereaction 39511 39518	anemia)
T524	adversereaction 39538 39550	neutropenia)
T525	adversereaction 39567 39584	thrombocytopenia)
T526	tradename 39655 39663	Marqibo.
T527	tradename 39698 39705	Marqibo
T528	adversereaction 39813 39837	Tumorlysissyndrome(TLS).
T529	adversereaction 39837 39840	TLS
T530	adversereaction 39878 39881	TLS
T531	tradename 40016 40024	Marqibo,
T532	adversereaction 40065 40106	Constipationandintestinal(bowel)blockage.
T533	adversereaction 40161 40194	constipationorintestinalblockage.
T534	adversereaction 40217 40242	stomacharea(abdomen)pain,
T535	adversereaction 40242 40250	bloating
T536	adversereaction 40252 40260	diarrhea
T537	adversereaction 40263 40269	nausea
T538	adversereaction 40271 40279	vomiting
T539	adversereaction 40293 40301	fatigue)
T540	tradename 40303 40310	Marqibo
T541	adversereaction 40422 40453	Liverproblemsthatcancausedeath.
T542	tradename 40453 40460	Marqibo
T543	adversereaction 40508 40539	liverproblemsthatcancausedeath.
T544	tradename 40605 40613	Marqibo.
T545	tradename 40656 40663	Marqibo
T546	tradename 40757 40764	Marqibo
T547	adversereaction 40775 40781	nausea
T548	adversereaction 40783 40788	fever
T549	adversereaction 40790 40798	diarrhea
T550	adversereaction 40800 40817	decreasedappetite
T551	adversereaction 40819 40832	sleepproblems
T552	tradename 40941 40949	Marqibo.
T553	tradename 41108 41115	Marqibo
T554	tradename 41273 41281	Marqibo.
T555	tradename 41316 41324	Marqibo,
T556	tradename 41394 41401	Marqibo
T557	tradename 41519 41527	Marqibo?
T558	activeingredient 41545 41563	vincristinesulfate
T559	inactiveingredient 41585 41594	mannitol,
T560	corecomposition 41594 41608	sphingomyelin,
T561	corecomposition 41608 41620	cholesterol,
T562	inactiveingredient 41620 41634	sodiumcitrate,
T563	inactiveingredient 41635 41646	citricacid,
T564	inactiveingredient 41646 41661	sodiumphosphate
T565	inactiveingredient 41664 41679	sodiumchloride.
T566	company 41768 41790	TalonTherapeutics,Inc.
